Stockscreener 앱 받기
5.40
1.69%
0.09
시간 외 거래:
5.37
-0.03
-0.56%
전일 마감가:
$5.31
열려 있는:
$5.17
하루 거래량:
36,729
Relative Volume:
0.44
시가총액:
$82.87M
수익:
-
순이익/손실:
-
주가수익비율:
-7.6142
EPS:
-0.7092
순현금흐름:
-
1주 성능:
+7.78%
1개월 성능:
+31.39%
6개월 성능:
+27.06%
1년 성능:
+318.60%
1일 변동 폭
$5.17
$5.56
1주일 범위
$5.09
$5.56
52주 변동 폭
$1.001
$7.00
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
ATHE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
5.40 | 76.24M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
ATHE: A Tale of Ups & Downs – 63.16% gain in 6 Months, 42.35% in 30 Days - investchronicle.com
SMCI’s Market Flip-Flop: Exploring the Volatility of 2025 Performance - investchronicle.com
Alterity CEO to provide corporate update on ATH434 development By Investing.com - Investing.com India
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK
Alterity Therapeutics completes placement By Investing.com - Investing.com UK
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Alterity Concludes Open-Label Trial Patient Visits - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics raises A$40M in placement - TipRanks
Alterity secures funding to advance MSA drug development - Investing.com India
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - stockhead.com.au
Most active stocks: US stocks with the highest trading volume today - Yahoo
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
symbol__ Stock Quote Price and Forecast - CNN
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Biotech Stocks: Longevity Company Stocks - Investing.com
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
Biggest Stock LosersToday’s Biggest Percentage Decliners - MarketBeat
Alterity Therapeutics LtdADR Shares Close the Week 40.3% HigherWeekly Wrap - Nasdaq
Most Volatile Stocks, What Investors Need to Know - MarketBeat
ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content
A Full List of Australia ADRs - Investing.com Australia
How Investors Can Identify and Successfully Trade Gap-Down Stocks - MarketBeat
What Investors Need to Know to Beat the Market - MarketBeat
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
알테리티 테라퓨틱스 (ATHE) 재무 분석
알테리티 테라퓨틱스 (ATHE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):